Because Mcl-1 has a very short half-life (usually referred to as 1 h) when compared to other antiapoptotic proteins, it may be possible to battle these tumors by sensitizing Mcl-1-dependent cancer cells to chemotherapy-induced apoptosis when Mcl-1 is inhibited [45]. This evidence concerns the gene MCL1 and cancer.